Product Quantum (Rs. Cr) Long Term Rating Short Term Rating
Bank Loan Ratings 12.10 ACUITE BBB | Stable | Reaffirmed -
Bank Loan Ratings 12.00 - ACUITE A3+ | Reaffirmed
Total Outstanding 24.10 - -
 

Rating Rationale

Acuite has reaffirmed the long-term rating of ACUITE BBB (read as ACUITE triple B) and the short-term rating of ACUITE A3+ (read as ACUITE A three plus) on the Rs. 24.10 Cr. bank facilities of Pharmalab India Private Limited. The outlook is 'Stable'.

Rationale for rating reaffirmation
The rating reaffirmation of PIPL takes into account improvement in the company’s operating performance of FY2023 as well as the healthy financial risk profile marked by moderate net-worth, low gearing and healthy debt protection metrics. The rating also draws comfort from the company’s experienced management with an established track record of operations and its reputed clientele. The rating is however constrained by the company’s working capital-intensive nature of operations and presence in a highly competitive and cyclical nature of the industry.

Going forward, ability of PIPL to maintain its scale of operations and profitability margins as per the estimated levels, while improving and maintaining an efficient working capital cycle will remain a key rating sensitivity factor.

Key Rating Drivers

Particulars Unit FY 23 (Actual) FY 22 (Actual)
Operating Income Rs. Cr. 132.14 120.90
PAT Rs. Cr. 12.84 6.89
PAT Margin (%) 9.72 5.70
Total Debt/Tangible Net Worth Times 0.16 0.30
PBDIT/Interest Times 12.74 8.44